Taysha Gene Therapies (NASDAQ:TSHA) filed a prospectus for a mixed shelf offering of up to $300 million. The preliminary prospectus is not an offer to sell. Filing Taysha Gene Therapies ...

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central ...

The stock options have an exercise price of $1.62 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four ...

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies ...

Taysha Gene Therapies (TSHA) is scheduled to report earnings on May 13, 2025. The last reported earnings were for reported on February 26, 2025 for Q4. The Actual Revenue was $2M, which beat the ...

Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Avi Kapoor Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" Neurogene (NASDAQ:NGNE ...

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the company ...

The Japanese firm has agreed to make a $50 million investment in Dallas-based Taysha in exchange for a 15% stake in the company, plus exclusive options to license two clinical-stage, single-gene ...

DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies ...

Taysha Gene Therapies (TSHA) announced that, on March 3, 2025, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, options to purchase ...